Sensitive manipulation of CAR T cell activity using a chimeric endocytosing receptor.
Boning ZhangJohn Victor NapoleonXin LiuQian LuoMadduri SrinivasaraoPhilip S LowPublished in: Journal for immunotherapy of cancer (2021)
We suggest this 'chimeric endocytosing receptor' can be exploited to manipulate not only CAR T cells but other ACTs following their reinfusion into patients. With efforts to develop ACTs to treat diseases including diabetes, heart failure, osteoarthritis, cancer and sickle cell anemia accelerating, we argue an ability to manipulate ACT activities postinfusion will be important.
Keyphrases
- cell therapy
- heart failure
- cardiovascular disease
- papillary thyroid
- type diabetes
- single cell
- rheumatoid arthritis
- mesenchymal stem cells
- cell free
- left ventricular
- glycemic control
- squamous cell carcinoma
- knee osteoarthritis
- iron deficiency
- bone marrow
- young adults
- cardiac resynchronization therapy
- insulin resistance